PhaseBio Pharmaceuticals Capital expenditures

Capital expenditures of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capital expenditures growth rates and interactive chart. Capital expenditures, commonly known as Capex, are funds used by a company to acquire, upgrade, and maintain physical or intangible assets such as property, buildings, an industrial plant, technology, software or equipment. Capex is often used to undertake new projects or investments by the firm. A company must invest over its lifetime into productive assets to maintain its competitiveness and ensure its survival.

Highlights and Quick Summary

  • Capital expenditures for the quarter ending June 29, 2021 was $-252 Thousand (a 89.47% increase compared to previous quarter)
  • Year-over-year quarterly Capital expenditures increased by 41.57%
  • Annual Capital expenditures for 2020 was $-1.31 Million (a 36.67% increase from previous year)
  • Annual Capital expenditures for 2019 was $-960 Thousand (a 706.72% increase from previous year)
  • Annual Capital expenditures for 2018 was $-119 Thousand (a -44.91% decrease from previous year)
  • Twelve month Capital expenditures ending June 29, 2021 was $-618 Thousand (a -30.33% decrease compared to previous quarter)
  • Twelve month trailing Capital expenditures decreased by -55.64% year-over-year
Trailing Capital expenditures for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$-618 Thousand $-887 Thousand $-1.31 Million $-1.39 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capital expenditures of PhaseBio Pharmaceuticals

Most recent Capital expendituresof PHAS including historical data for past 10 years.

Interactive Chart of Capital expenditures of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Capital expenditures for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-0.25 $-0.13
2020 $-0.06 $-0.18 $-0.52 $-0.56 $-1.31
2019 $-0.14 $-0.4 $-0.35 $-0.08 $-0.96
2018 $-0.09 $-0.0 $-0.02 $-0.01 $-0.12
2017 $-0.01 $-0.2 $-0.22

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.